Kieffer Tara Lynn
SEC CIK 1834835 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| ENTA | ENANTA PHARMACEUTICALS INC | SVP, New Product Dev | 33.9K | — | $158.4K | 20 | 2021-11-19 | 2026-02-12 |
Most active insiders at ENTA, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Luly Jay R. | Pres, CEO, Dir | — | $67.5K |
| 2 | Or Yat Sun | CSO | — | $34.0K |
| 3 | Kieffer Tara Lynn | Chief Product Strategy Off | — | $30.0K |
| 4 | Luu Brendan | Chief Business Off | — | $19.8K |
| 5 | Trout Harry R. III | See Remarks | — | $13.0K |
| 6 | Rottinghaus Scott T. | Chief Medical Off | — | $11.4K |
| 7 | Capps Kathleen S. | See Remarks | — | $7,486 |
| 8 | Kowalsky Matthew Paul | CLO | — | — |
Transactions 20
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-13 | 2026-02-12 | ENTA | ENANTA PHARMACEUTICALS INC | Kieffer Tara Lynn | Chief Product Strategy Off | F - Tax | $14.25 | -3,257 | 33.9K | -9% | -$46.4K | |
| M | 2026-02-13 | 2026-02-12 | ENTA | ENANTA PHARMACEUTICALS INC | Kieffer Tara Lynn | Chief Product Strategy Off | A - Grant | $0.00 | +6,562 | 32.2K | +26% | $0 |
| 2025-12-05 | 2025-12-05 | ENTA | ENANTA PHARMACEUTICALS INC | Kieffer Tara Lynn | Chief Product Strategy Off | S - Sale | $14.23 | -2,106 | 30.6K | -6% | -$30.0K | |
| 2025-12-03 | 2025-12-01 | ENTA | ENANTA PHARMACEUTICALS INC | Kieffer Tara Lynn | Chief Product Strategy Off | F - Tax | $14.12 | -753 | 32.7K | -2% | -$10.6K | |
| 2025-02-14 | 2025-02-12 | ENTA | ENANTA PHARMACEUTICALS INC | Kieffer Tara Lynn | Chief Product Strategy Off | A - Grant | $0.00 | +7,500 | 36.8K | +26% | $0 | |
| 2025-02-14 | 2025-02-12 | ENTA | ENANTA PHARMACEUTICALS INC | Kieffer Tara Lynn | Chief Product Strategy Off | F - Tax | $5.59 | -3,326 | 33.5K | -9% | -$18.6K | |
| 2024-12-10 | 2024-12-06 | ENTA | ENANTA PHARMACEUTICALS INC | Kieffer Tara Lynn | Chief Product Strategy Off | S - Sale | $8.06 | -2,283 | 29.3K | -7% | -$18.4K | |
| 2024-12-03 | 2024-12-01 | ENTA | ENANTA PHARMACEUTICALS INC | Kieffer Tara Lynn | Chief Product Strategy Off | F - Tax | $8.60 | -753 | 31.6K | -2% | -$6,476 | |
| 2024-06-17 | 2024-06-17 | ENTA | ENANTA PHARMACEUTICALS INC | Kieffer Tara Lynn | Chief Product Strategy Off | S - Sale | $12.33 | -7,266 | 32.3K | -18% | -$89.6K | |
| 2024-02-14 | 2024-02-12 | ENTA | ENANTA PHARMACEUTICALS INC | Kieffer Tara Lynn | Chief Product Strategy Off | F - Tax | $12.41 | -973 | 39.6K | -2% | -$12.1K | |
| 2024-02-14 | 2024-02-12 | ENTA | ENANTA PHARMACEUTICALS INC | Kieffer Tara Lynn | Chief Product Strategy Off | A - Grant | $0.00 | +3,320 | 40.6K | +9% | $0 | |
| 2023-12-06 | 2023-12-05 | ENTA | ENANTA PHARMACEUTICALS INC | Kieffer Tara Lynn | SVP, New Prod. Strat, Dev | S - Sale | $9.63 | -2,125 | 37.3K | -5% | -$20.5K | |
| 2023-12-05 | 2023-12-01 | ENTA | ENANTA PHARMACEUTICALS INC | Kieffer Tara Lynn | SVP, New Prod. Strat, Dev | F - Tax | $9.49 | -753 | 39.4K | -2% | -$7,146 | |
| M | 2023-02-15 | 2023-02-13 | ENTA | ENANTA PHARMACEUTICALS INC | Kieffer Tara Lynn | SVP, New Product Dev | A - Grant | $0.00 | +21.0K | 46.9K | +81% | $0 |
| 2023-02-15 | 2023-02-13 | ENTA | ENANTA PHARMACEUTICALS INC | Kieffer Tara Lynn | SVP, New Product Dev | F - Tax | $52.77 | -6,725 | 40.1K | -14% | -$354.9K | |
| 2022-12-05 | 2022-12-01 | ENTA | ENANTA PHARMACEUTICALS INC | Kieffer Tara Lynn | SVP, New Product Dev | F - Tax | $44.33 | -498 | 25.9K | -2% | -$22.1K | |
| D | 2022-11-28 | 2022-11-23 | ENTA | ENANTA PHARMACEUTICALS INC | Kieffer Tara Lynn | SVP, New Product Dev | A - Grant | $0.00 | +18.5K | 26.4K | +235% | $0 |
| M | 2022-02-15 | 2022-02-14 | ENTA | ENANTA PHARMACEUTICALS INC | Kieffer Tara Lynn | SVP, New Product Dev | A - Grant | $0.00 | +1,616 | 8,416 | +24% | $0 |
| 2022-02-15 | 2022-02-14 | ENTA | ENANTA PHARMACEUTICALS INC | Kieffer Tara Lynn | SVP, New Product Dev | F - Tax | $62.49 | -552 | 7,864 | -7% | -$34.5K | |
| D | 2021-11-23 | 2021-11-19 | ENTA | ENANTA PHARMACEUTICALS INC | Kieffer Tara Lynn | SVP, New Product Dev | A - Grant | $0.00 | +6,800 | 6,800 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations